650 East Kendall Street
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com.
Stock Symbol: TAK
Science is the foundation for everything we do at Takeda. We connect to our 240- year history and our strong values through our pursuit of life-transforming science where we embrace a culture of collaboration, pursue modalities based on validated targets, evaluate real-world impact and generate data that may enable accelerated development and regulatory pathways.
1493 articles about Takeda
A U.S. federal court upheld a prior ruling in favor of Roche’s Genentech, finding that its blockbuster hemophilia treatment Hemlibra did not infringe on patent protections held by Takeda’s Baxalta.
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries
Takeda announced five new partnerships to its Global Corporate Social Responsibility Program, which contribute to strengthening health systems in low- and middle-income countries.
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO ® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease.
Patient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge
Takeda Canada Inc. is pleased to announce two winners of the 2023 Takeda Canada Digital Health Innovation Challenge, a competition to identify and support innovative digital health solutions to improve patient outcomes and experiences.
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
Takeda announced positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 inhibitor with next generation selectivity, in people with active psoriatic arthritis.
As biosimilars and next-generation treatments for Crohn’s disease enter the market, AbbVie will be knocked from its place of longtime dominance, contends data and analytics firm GlobalData.
Amid a supply shortage of the attention-deficit/hyperactivity disorder and binge-eating disorder medication, the regulator has cleared a slew of generic drugs of Takeda’s Vyvanse pill.
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced it has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE in Japan.
BridGene Biosciences, Inc. announced a significant preclinical milestone in its collaboration with Takeda.
Many products are facing the loss of their patents or exclusivity clauses. Here’s what to expect in the coming months.
The companies partnered to develop the antibody transport vehicle in late 2021, but will continue their 2018 agreement to pursue other drugs in preclinical development.
Despite beating analyst expectations, Takeda sustains a mid-stage defeat in a rare genetic disorder, leaving the fate of an investigational enzyme replacement therapy uncertain.
Takeda announced strong financial results for the first quarter of fiscal year 2023. Takeda chief financial officer, Costa Saroukos, commented: “Our Growth & Launch Products continued to drive revenue growth in the first quarter of FY2023, contributing to a core operating profit margin of 30.8%.
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK) today announced that data from the Phase 2 study of orexin receptor 2 (OX2R) agonist TAK-994 in patients with narcolepsy type 1 (NT1) was published in The New England Journal of Medicine.
Following the regulator’s request for more data beyond the scope of its Phase III TIDES trial, Takeda decided to voluntarily withdraw the Biologics License Application for its TAK-003 dengue vaccine.
The companies have signed two other pacts over the last year. In the latest deal, Takeda gains access to F-star’s platform to produce tetravalent antibodies for undisclosed oncology targets.
F-star, an invoX Company, Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies
F-star Therapeutics , an invoX company (“F-star”) , today announced that it has entered into a strategic discovery collaboration and licence agreement with Takeda.
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda presented favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover trial evaluating the safety and efficacy of TAK-755 replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura, and pharmacokinetics characteristics of TAK-755, as well as long-term data on TAK-755 prophylaxis from a Phase 3b continuation study.
Here are the top biotech companies in California hiring now on BioSpace’s life sciences–focused job board.
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA ® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting.